Hoxton Planning & Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$533K Buy
2,119
+66
+3% +$14.2K 0.14% 119
2026
Q1
$447K Sell
2,053
-62
-3% -$13.8K 0.13% 118
2025
Q4
$483K Buy
2,115
+57
+3% +$13K 0.14% 115
2025
Q3
$477K Buy
2,058
+22
+1% +$4.48K 0.15% 114
2025
Q2
$378K Sell
2,036
-93
-4% -$17.3K 0.13% 132
2025
Q1
$446K Buy
2,129
+76
+4% +$14.8K 0.17% 115
2024
Q4
$365K Buy
2,053
+223
+12% +$41K 0.14% 130
2024
Q3
$361K Buy
1,830
+338
+23% +$63.1K 0.14% 136
2024
Q2
$256K Sell
1,492
-45
-3% -$7.45K 0.12% 129
2024
Q1
$280K Buy
1,537
+162
+12% +$27.9K 0.13% 120
2023
Q4
$213K Sell
1,375
-112
-8% -$16.3K 0.11% 138
2023
Q3
$222K Sell
1,487
-168
-10% -$24.7K 0.14% 125
2023
Q2
$223K Buy
1,655
+267
+19% +$39.2K 0.14% 132
2023
Q1
$221K Sell
1,388
-20
-1% -$3.06K 0.12% 145
2022
Q4
$228K Buy
+1,408
New +$216K 0.12% 143

Other funds holding ABBV

Hoxton Planning & Management's ABBV Position: Q2 2026 in Review

Hoxton Planning & Management increased its AbbVie (ABBV) stake by 3.2% in Q2 2026, buying an estimated $14.2K and bringing the position to 2,119 shares worth $533K. The position accounts for 0.14% of the portfolio, ranked #119.

Hoxton Planning & Management first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 1,295 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Hoxton Planning & Management held 2,119 shares of AbbVie worth $533K as of Q2 2026.
  • Hoxton Planning & Management bought 66 AbbVie shares in Q2 2026, an estimated $14.2K.
  • AbbVie made up 0.14% of Hoxton Planning & Management's portfolio in Q2 2026, its #119 holding.
  • Hoxton Planning & Management first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
  • 1,295 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Hoxton Planning & Management's 13F filing for Q2 2026, filed 16 Jul 2026.